Avior Wealth Management’s Stoke Therapeutics STOK Stock Holding History
Bought
Maintained
Sold
Other funds holding STOK
ST
LCM
RG
BBA
RI
CAC
Avior Wealth Management's STOK Position: Q2 2024 in Review
Avior Wealth Management sold out of Stoke Therapeutics (STOK) in Q2 2024, closing a stake of 5 shares — an estimated $67 sold.
Avior Wealth Management first reported a position in STOK in Q1 2024 and held it in 1 quarter. The position peaked at $67 in Q1 2024. 114 funds tracked by Wall St. Rank hold STOK as of Q2 2024.
- Avior Wealth Management reported no remaining Stoke Therapeutics position as of Q2 2024 after selling out during the quarter.
- Avior Wealth Management sold 5 Stoke Therapeutics shares in Q2 2024, an estimated $67.
- Avior Wealth Management first reported a position in Stoke Therapeutics in Q1 2024 and held it in 1 quarter.
- Avior Wealth Management's Stoke Therapeutics position peaked at $67 in Q1 2024.
- 114 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2024.
Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.